Response: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark

Lignende værker

• Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark
  af: Aksan, Ayşegül, et al.
  Udgivet: (2019)
• An Economic Analysis of Ferric Derisomaltose versus Ferric Carboxymaltose in the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Norway, Sweden, and Finland
  af: Pollock, Richard F, et al.
  Udgivet: (2021)
• A budget impact analysis of parenteral iron treatments for iron deficiency anemia in the UK: reduced resource utilization with iron isomaltoside 1000
  af: Pollock, Richard F, et al.
  Udgivet: (2017)
• Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials
  af: Wolf, Myles, et al.
  Udgivet: (2020)
• Ferric carboxymaltose in the treatment of iron deficiency in pediatric inflammatory bowel disease
  af: Carman, Nicholas, et al.
  Udgivet: (2019)